References
- StewartWCClinical Practice of GlaucomaThorofare, NJSLACK, Inc1990
- BaudouinCAllergic reaction to topical eyedropsCurr Opin Allergy Clin Immunol2005545946316131924
- IshibashiTYokoiNKinoshitaSComparison of the short-term effects on the human corneal surface of topical timolol maleate with and without benzalkonium chlorideJ Glaucoma20031248649014646684
- KatzLJTwelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertensionJ Glaucoma20021111912611912359
- LewisRAKatzGJWeissMJTravoprost BAC-free Study GroupTravoprost 0.004% with and without benzalkonium chloride: a comparison of safety and efficacyJ Glaucoma2007169810317224758
- StewartWCPfiefferNMathisHMMeta-analysis of articles evaluating routine intraocular pressure control for monotherapy in the United States and GermanyEur J Ophthalmol2009In press
- CamrasCBAlmAWatsonPStjernschantzJLatanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Latanoprost Study GroupsOphthalmology1996103191619248942890
- SchiffmanRMChristiansonMDJacobsenGHirschJDReisBLReliability and validity of the Ocular Surface Disease IndexArch Ophthalmol200011861562110815152
- RosnerBFundamentals of BiostatisticsBoston, MADuxbury Press1982301304
- StewartWCDayDGStewartJAHolmesKTJenkinsJNShort-term ocular tolerability of dorzolamide 2% and brinzolamide 1% versus placebo in primary open-angle glaucoma and ocular hypertension subjectsEye20041890591015002017
- AlmACamrasCBWatsonPGPhase III latanoprost studies in Scandinavia, the United Kingdom and the United StatesSurv Ophthalmol199741Suppl 2S105S1109154285
- SiegelSNon Parametric Statistics. Series in PsychologyNew York, NYMcGraw Hill19566367
- StewartWCStewartJALeechJNAcute and chronic ocular symptoms of dorzolamide 2% compared with placeboJ Glaucoma20031215115512671470
- BookSAEssentials of StatisticsNew York, NYMcGraw Hill, Book Company1978
- LeungEWMedeirosFAWeinrebRNPrevalence of ocular surface disease in glaucoma patientsJ Glaucoma20081735035518703943
- BaudouinCDetrimental effect of preservatives in eyedrops: implications for the treatment of glaucomaActa Ophthalmol20088671672618537937
- BaudouinCRianchoLWarnetJ-MBrignoleFIn vitro studies of antiglaucomatous prostaglandin analogues: Travoprost with and without benzalkonium chloride and preserved latanoprostInvest Ophthalmol Vis Sci2007484123412817724196
- YeeRWNorcomEGZhaoXCComparison of the relative toxicity of travoprost 0.004% without benzalkonium chloride and latanoprost 0.005% in an immortalized human cornea epithelial cell culture systemAdv Ther20062351151917050493
- KahookMNoeckerRJComparison of corneal and conjunctival changes after dosing of travoprost preserved with sofZia, latanoprost with 0.02% benzalkonium chloride, and preservative-free artificial tearsCornea20082733934318362664
- HenryJCPeaceJHStewartJAStewartWCEfficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapyClin Ophthalmol20082613621
- StewartWCStewartJALeechJNJacksonALCorneal punctate staining with latanoprost, bimatoprost and travoprostJ Glaucoma20031247547914646682
- McCareyBEdelhauserHIn vivo corneal epithelial permeability following treatment with prostaglandin analogs with or without benzalkonium chlorideJ Ocul Pharmacol Ther20072344545117941807
- DayDGSharpeEDAtkinsonMJStewartJAStewartWCThe clinical validity of the treatment satisfaction survey for intraocular pressure in ocular hypertensive and glaucoma patientsEye20062058359015933751
- FreemanEEMuñozBWestSKJampelHDFriedmanDSGlaucoma and quality of life: the Salisbury Eye EvaluationOphthalmology200811523323817655930